Xian Janssen Announces Plans to Build State-of-the-Art Manufacturing Site in China

Xian Janssen Announces Plans to Build State-of-the-Art Manufacturing Site in China

Strategic investment designed to help accelerate growth in China and in broader Pan- Asia region 

XI'AN, CHINA, NOVEMBER 14, 2013 – Xian Janssen Pharmaceutical Ltd. (XJP), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and the Xi'an High-Tech Industries Development Zone announced today the signing of a memorandum of understanding to build a large state-of-the art manufacturing facility to serve China and the broader Pan-Asia region.  

The new site, which will be built in the rapidly developing Xi'an High-Tech Industries Development Zone, will feature world-class manufacturing technologies, advanced quality systems, and significantly greater capacity than its current Xi'an-based facilities.  

The new 267,000-square-meter site will replace XJP's existing site in Xi'an with the objective of becoming the company's supply-chain hub for innovation in Asia, serving the rapidly expanding needs of China and other markets in the region. 

This announcement is another example of XJP's and Johnson & Johnson's strong commitment to invest in innovation to grow its business in Asia.  Construction of the new site will start in 2014. 

At a signing ceremony held in Xi'an today, Jesse Wu, Chairman, Johnson & Johnson China, said: "For 28 years, XJP's Xi'an site has delivered high-quality products to patients around the country. It has won many national and industrial awards and recognition for its leading manufacturing capabilities. This next-generation, hi-tech facility will greatly increase our ability to deliver our innovative products to patients."  

Mr. Wu added: "Providing the people of China with high-quality products that meet their unique needs is our most important objective. By working closely with our local strategic partners, we are committed to meeting the increasing demand for healthcare services in the country."

The construction of the new plant represents the extension of XJP's longstanding strategic partnership with the Shaanxi Provincial and Xi'an Municipal Governments and is aligned with their efforts to make the High-Tech Industries Development Zone a world-leading hi-tech zone. It is also in line with Xian Janssen Pharmaceutical's long-term strategy of implementing high-quality manufacturing, meeting all environmental, health, safety and sustainability standards.

"Xian Janssen has been making significant contributions to the development of Shaanxi Province since its establishment in 1985," said Jinzhu Li, Vice Governor of Shaanxi Province. "Dr. Paul Janssen, the founder of Xian Janssen Pharmaceutical, was a pioneer both in enhancing Chinese healthcare and protecting our historical heritage through his commitment to preserving the Terracotta Warriors. We look forward to continuing our collaboration with the company in the future." 

Other notable guests attending the signing ceremony were Minzhou Wei, Secretary of Xi'an Committee of the CPC; Jun Dong, Mayor of Xi'an; Hongzhuan Zhao, Head of Xi'an High-Tech Industries Development Zone's Administrative Committee from Shaanxi Province; Cliff Holland, Corporate Vice President of Johnson & Johnson; Thad Huston, President of Xian Janssen Pharmaceutical Ltd; and Paul McKenzie, Vice President, Manufacturing & Technical Operations, Janssen Supply Chain. 

"Xian Janssen is the first multinational healthcare company to enter the Zone," said Xi'an High-Tech Industries Development Zone's Hongzhuan Zhao. "We appreciate its contributions to China and Xi'an in past decades, and welcome its arrival in the High-tech Zone. With this move, we expect to further enhance our standards and improve the diversity within the Zone."

 "The new Xian Janssen site will play a key role as a source of innovation in our global network," said Janssen's Mr. McKenzie. "It is an opportunity to increase our ability to best serve the people of China and the region." 


About Xian Janssen

Xian Janssen Pharmaceutical Ltd. is one of the Janssen Pharmaceutical Companies of Johnson & Johnson. It is one of China's largest pharmaceutical companies and among the earliest multinational pharmaceutical companies to enter China simultaneous with the opening up of China's economy.

 Since its establishment in 1985, Xian Janssen has been committed to providing Chinese patients with high-quality, innovative products that fulfill unmet medical needs in psychiatry, neurology, oncology, immunology, and gastrointestinal and fungal diseases. 

Based on the company's Credo and spirit of caring, Xian Janssen has been an active corporate citizen, conducting over 50 cooperative projects in the areas of medicine, public health, medical R&D, and corporate social responsibility.

# # #

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Xian Janssen Pharmaceutical Ltd., any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson.  Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; impact of business combinations; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies.  A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.  None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.)

For more information, please contact: 

Maggie Sun Yan

Xian Janssen Pharmaceutical Ltd.

Tel: 010-58218458

Cell: 18618146560

E-mail: [email protected]